Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacokinetics of apatinib in healthy male Caucasian, Japanese and Chinese subjects.

Next Previous
Search
Trial Profile

Pharmacokinetics of apatinib in healthy male Caucasian, Japanese and Chinese subjects.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 25 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivoceranib (Primary)
  • Indications Adenoid cystic carcinoma; Breast cancer; Cholangiocarcinoma; Colorectal cancer; Fallopian tube cancer; Gastric cancer; Liver cancer; Lung cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Osteosarcoma; Ovarian cancer; Peritoneal cancer; Small cell lung cancer; Soft tissue sarcoma; Solid tumours; Uterine cancer
  • Focus Pharmacokinetics

Most Recent Events

  • 28 Sep 2017 New trial record
  • 01 Sep 2017 Results assessing Pharmacokinetics of apatinib in healthy Caucasian, Japanese and Chinese subjects following a single-dose administration, were published in the Clinical Pharmacology in Drug Development Conference: 2017 Annual Meeting of the American College of Clinical Pharmacology.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top